Abstract: Human Immunodefficiency Virus (HIV) is a virus that decreases the human immunity
INTRODUCTION
Human Immunodeficiency Virus (HIV) is a major problem that threatens Indonesia and many countries around the world. 1 HIV is a type of virus that lowers the immune system, therefore the people infected with this virus become susceptible to various infections.
2 Acquired Immunodeficiency Syndrome (AIDS) is a stage of infection that occurs when the immune system is damaged and a person becomes susceptible to infection. A person has been diagnosed with AIDS when CD4 lymphocytes count falls below 200 cells / μL. HIV is found primarily in blood, sperm fluid, vaginal fluid and breast milk. 2, 3 According to United Nations Programme on HIV/AIDS (UNAIDS) on 2012, there were 35.3 million people infected with HIV worldwide and 2.3 million more people each year. 4 The data of Indonesia Health Profile on 2012 showed that there were 21,511 new cases of HIV and increased by 35% to 29,037 new cases of HIV infection on 2013. On 2013, there were 174 new HIV cases in South Kalimantan. 5 Drugs used for HIV currently are antiretroviral (ARV) with the aim of suppressing the development of virus to the maximum until undetected. 6 The standard guidelines for the management of HIV in Indonesia are the provision of 1 nucleoside reverse transcriptase inhibitors (NRTIs) and 2 non-nucleoside reverse transcriptase inhibitors (NNRTIs) known as combination therapy or ARV regimen as first line. It is expected that within six months of therapy there will be better clinical and immunological development. 6 The success of ARV therapy programs can be achieved by following monitoring activities. A method of monitoring the success of therapy is by examining CD4 lymphocytes count every six months. Data of CD4 lymphocytes count when starting ARV therapy and the proliferation of CD4 lymphocyte counts evaluated every six months is necessary to determine immunological failure. 6 It is essential to monitor ARV treatment responses through changes of CD4 lymphocyte count as a sign of an immunologic response. On the other hand, research on the evaluation of CD4 lymphocyte count responses in HIV patients who were given antiretroviral therapy requires more attention. In Indonesia, there are no a lot of researches reveal about the monitoring of antiretroviral therapy, especially at Ulin General Hospital Banjarmasin. Based on that reason, this research needs to be done.
RESEARCH METHODS
This research uses analytic observational method with retrospective cross-sectional approach. The populations of this research were patients diagnosed with HIV at Ulin General Hospital Banjarmasin on 2013-2015. The subjects of this research were taken from medical record data and laboratory results of HIV patients at Ulin General Hospital Banjarmasin using purposive sampling technique. The subjects were taken based on the inclusion criteria: the subjects should be 20-64 years old, have complete medical record data, has been receiving antiretroviral therapy for six months and has two data of CD4 lymphocytes count. The exclusion criteria for this research were patients who died before six months of antiretroviral therapy and pregnant HIV patients.
The instruments of this research are medical record data and laboratory result of CD4 lymphocytes count of HIV patients at Ulin General Hospital Banjarmasin. The variables studied in this research were the CD4 lymphocytes count before and after ARV therapy expressed in units of cells / μL calculated by Alere Pima CD4 tool in Immunoserology Division of Clinical Pathology Laboratory of Ulin General Hospital Banjarmasin. The data is processed by using computerized system using SPSS programme for Windows. 
The normality test used in this research is the Kolmogorov-Smirnov normality test. Kolmogorov-Smirnov test results showed the distribution of CD4 lymphocyte count data before therapy was normally distributed with p = 0.010, whereas the distribution of CD4 lymphocyte count data after treatment was not normally distributed with p = 0.001.
The data analysis test was continued with Wilcoxon test to know the difference between CD4 lymphocyte count group before and after ARV therapy because the data distribution of one group was not normal. Wilcoxon test results showed p = 0,000 (p <0.05) which showed significant difference between CD4 lymphocyte count before and after ARV therapy.
The results of this statistical test are consistent with the previous hypothesis that there is a significant difference between CD4 lymphocyte counts before and after ARV therapy. ARV therapy becomes an effective way to increase CD4 lymphocytes count in people with HIV.
3
CD4 lymphocytes are one component of lymphocytes that play a role in the immune system. HIV virus will enter, infect and replicate in CD4 lymphocytes. 3, 10 This process of replication leads to progressive death and decreased CD4 lymphocyte count progressively. 10 ARV therapy is still the only effective way to increase CD4 lymphocytes count in people with HIV. The mechanism of action of ARV is to inhibit viral replication and CD4 lymphocyte death. 3 This result is in The distribution of first-line ARV regimens administered to HIV/AIDS patients at Ulin General Hospital Banjarmasin on 2013-2015 can be seen in table 2. There are 34 subjects (61.82%) received a combination regimen of Zidovudine + Lamivudine + Nevirapine (AZT + 3TC + NVP) as the beginning of ARV therapy, followed by Zidovudine + Lamivudine + Epavirenz (AZT + 3TC + EFV) of 15 subjects (27.27%), Tenofovir + Lamivudine + Epavirenz (TDF + 3TC + EFV) of 4 subjects (7.27%), Zidovudine + Lamivudine + Nevirapin (TDF + 3TC + NVP) of 2 subjects (3.64%). This result is in accordance with research conducted by Yasin et al at a Jogjakarta Education Hospital, it was showed that the Zidovudine + Lamivudine + Nevirapin (AZT + 3TC + NVP) regimen was the most widely used of 61.97%, followed by AZT+3TC+EFV, TDF+3TC+EFV and TDF+3TC+NVP. The use of all four types of regimens at Ulin General Hospital Banjarmasin is in accordance with national guidelines for the management of HIV/AIDS infection and antiretroviral therapy in adults with the most widely used AZT + 3TC + NVP and AZT + 3TC + EFV regimens. 6, 7 The mean rate of CD4 lymphocyte counts of HIV/AIDS patients based on the type of ARV regimen showed a varied increase in the four types of ARV regimens. The AZT + 3TC_NVP regimen showed a mean rate change of 101.94 cells /μL, the AZT + 3TC + EFV regimen showed a mean rate change of 93.53 cells /μL. The TDF + 3TC + EFV regimen showed a mean rate change of 73.5 cells / μL. The TDF + 3TC + NVP regimen showed a change of -31.5 cells / μL. The mean of this change can be seen in table 3. 
CONCLUSIONS
Based on the research results, the mean rate of CD4 lymphocytes count in HIV patients before antretroviral therapy at Ulin General Hospital Banjarmasin was 131.73 cells / Μl; whereas, the mean rate of CD4 lymphocytes count in HIV patients following antiretroviral therapy at Ulin General Hospital Banjarmasin was 224.45 cells/μL. From these two results, it can be concluded that there is a significant difference of CD4 lymphocytes count in HIV patients before and after antiretroviral therapy at Ulin General Hospital Banjarmasin.
